ECSP088884A - Compuestos heterociclicos fusionados y su uso como moduladores de mglur5 - Google Patents

Compuestos heterociclicos fusionados y su uso como moduladores de mglur5

Info

Publication number
ECSP088884A
ECSP088884A EC2008008884A ECSP088884A ECSP088884A EC SP088884 A ECSP088884 A EC SP088884A EC 2008008884 A EC2008008884 A EC 2008008884A EC SP088884 A ECSP088884 A EC SP088884A EC SP088884 A ECSP088884 A EC SP088884A
Authority
EC
Ecuador
Prior art keywords
fusioned
mglur5
modulators
compounds
heterociclical
Prior art date
Application number
EC2008008884A
Other languages
English (en)
Inventor
Methvin Isaac
Abdelmalik Slassi
Louise Edwards
Tao Xin
Karolina Nilsson
Kenneth Granberg
Tomislav Stefanac
Peter Dove
Andreas Waallberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP088884A publication Critical patent/ECSP088884A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención está dirigida a nuevos compuestos, aun proceso para su preparación y su uso en terapia y las composiciones farmacéuticas que comprenden los nuevos compuestos.
EC2008008884A 2006-05-05 2008-11-12 Compuestos heterociclicos fusionados y su uso como moduladores de mglur5 ECSP088884A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79766306P 2006-05-05 2006-05-05

Publications (1)

Publication Number Publication Date
ECSP088884A true ECSP088884A (es) 2008-12-30

Family

ID=38668441

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008884A ECSP088884A (es) 2006-05-05 2008-11-12 Compuestos heterociclicos fusionados y su uso como moduladores de mglur5

Country Status (19)

Country Link
US (1) US20070259860A1 (es)
EP (1) EP2027129A2 (es)
JP (1) JP2009536213A (es)
KR (1) KR20090018935A (es)
CN (1) CN101484455A (es)
AR (1) AR060811A1 (es)
AU (1) AU2007248292A1 (es)
BR (1) BRPI0710980A2 (es)
CA (1) CA2650255A1 (es)
CL (1) CL2007001178A1 (es)
EC (1) ECSP088884A (es)
IL (1) IL194815A0 (es)
MX (1) MX2008013834A (es)
NO (1) NO20084852L (es)
RU (1) RU2008141511A (es)
TW (1) TW200808800A (es)
UY (1) UY30308A1 (es)
WO (1) WO2007130824A2 (es)
ZA (1) ZA200809019B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200821305A (en) * 2006-10-05 2008-05-16 Astrazeneca Ab MGluR5 modulators
WO2009054794A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Amino 1,2,4-triazole derivatives as modulators of mglur5
WO2009054787A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,4-triazole carboxylic acid derivatives as modulators of mglur5
TW200922586A (en) * 2007-10-26 2009-06-01 Astrazeneca Ab Thiophene 1,2,4-triazole derivatives as modulators of mGluR5
WO2009054785A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,4-triazole ether derivatives as modulators of mglur5
WO2009054790A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Amide linked heteroaromatic derivatives as modulators of mglur5
WO2009054791A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5
WO2009054786A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5
KR20110101164A (ko) * 2008-12-18 2011-09-15 아스트라제네카 아베 1-〔5-(3-클로로-페닐)-이소옥사졸-3-일〕-에타논 및 (ｒ)-1-〔5-(3-클로로-페닐)-이속사졸-3-일〕-에탄올의 신규 제조 방법
JP5620129B2 (ja) * 2009-03-19 2014-11-05 富士フイルム株式会社 光学フィルム、位相差板、楕円偏光板、液晶表示装置、及び化合物
WO2011007756A1 (ja) 2009-07-13 2011-01-20 武田薬品工業株式会社 複素環化合物及びその用途
WO2011082010A1 (en) 2009-12-29 2011-07-07 Eli Lilly And Company Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia
WO2012029991A1 (en) 2010-09-02 2012-03-08 Takeda Pharmaceutical Company Limited Fused triazoles for the treatment or prophylaxis of mild cognitive impairment
PE20151979A1 (es) 2013-01-23 2016-01-15 Astrazeneca Ab Compuestos quimicos
EP2857387A1 (en) 2013-10-07 2015-04-08 Boehringer Ingelheim International Gmbh Process for manufacturing 1,6-dihydro-6-oxo-4-pyridazine carboxylic acid
TWI891782B (zh) 2020-05-06 2025-08-01 德商拜耳廠股份有限公司 作為殺蟲劑之新穎雜芳基三唑化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056315A1 (en) * 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of pain
US7074809B2 (en) * 2002-08-09 2006-07-11 Astrazeneca Ab Compounds
TW200812986A (en) * 2002-08-09 2008-03-16 Nps Pharma Inc New compounds
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
BRPI0507495A (pt) * 2004-02-18 2007-07-10 Astrazeneca Ab composto, composição farmacêutica, uso do composto método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5
JP5084269B2 (ja) * 2004-02-18 2012-11-28 アストラゼネカ アクチボラグ テトラゾール化合物及び代謝共役型グルタミン酸受容体アンタゴニストとしてのそれらの使用

Also Published As

Publication number Publication date
CL2007001178A1 (es) 2008-01-18
KR20090018935A (ko) 2009-02-24
WO2007130824A3 (en) 2008-05-22
US20070259860A1 (en) 2007-11-08
AU2007248292A1 (en) 2007-11-15
UY30308A1 (es) 2007-11-30
IL194815A0 (en) 2009-08-03
ZA200809019B (en) 2009-08-26
JP2009536213A (ja) 2009-10-08
EP2027129A2 (en) 2009-02-25
BRPI0710980A2 (pt) 2011-05-31
RU2008141511A (ru) 2010-06-20
NO20084852L (no) 2009-01-14
AR060811A1 (es) 2008-07-16
TW200808800A (en) 2008-02-16
WO2007130824A2 (en) 2007-11-15
MX2008013834A (es) 2008-11-10
AU2007248292A8 (en) 2008-12-04
CA2650255A1 (en) 2007-11-15
CN101484455A (zh) 2009-07-15

Similar Documents

Publication Publication Date Title
ECSP088884A (es) Compuestos heterociclicos fusionados y su uso como moduladores de mglur5
ECSP10010015A (es) Inhibidores de proteasoma
UY31806A (es) Compuestos de tiazole y oxazole de sulfonamida de benceno
CL2008002319A1 (es) Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CR11623A (es) Compuestos
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
CR20160475A (es) Derivados de ácido 1-amino-2-ciclobutiletilborónico
CL2008001815A1 (es) Compuestos derivados de indazol; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar cancer.
CR20160014A (es) Compuestos de éster boronato y composiciones farmacéuticas de los mismos
CR10149A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico
CL2008001835A1 (es) Uso de compuestos derivados de guaninas policiclicas para tratar la inflamacion; compuestos derivados de guanina; y compocicion farmaceutica que los comprende.
UY30610A1 (es) Moduladores de mglur5
CL2009001484A1 (es) Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia.
UY30304A1 (es) Moduladores de mglur5 i
UY30195A1 (es) Derivados de fenetanolamina, procedimiento de preparacion, composiciones que los contienen y aplicaciones
ECSP088288A (es) DERIVADOS DE 7-(2-AMINO-1-HIDROXI-ETIL)-4-HIDROXIBENZOTIAZOL-2(3H)-ONA COMO AGONISTAS DE LOS ADRENOCEPTORES ß2
UY30808A1 (es) Derivados de benzotiazolonas, composiciones conteniéndolos y aplicaciones
UY31990A (es) Nuevos derivados
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
HN2008000088A (es) Heterociclicos de 1,4-dihidropiridina- fusionada, procesos para preparar los mismos, su uso y las composiciones que los contienen.
UY30307A1 (es) Moduladores de mglur5 vi
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
UY30305A1 (es) Moduladores de mglur5 iv
CL2007003223A1 (es) Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades.
CR11391A (es) Derivados 1,2,4-triazol amino como moduladores de mglur5